Invasive infections with Salmonella species are usually treated with fluoroquinolones or extended-spectrum b-lactams. Quinolone resistance results in reduced susceptibility to fluoroquinolones, leaving health-care professionals with limited resources for treatment of salmonellosis. Several mechanisms contribute to the development of quinolone resistance in Salmonella and these include: mutations in the quinolone resistance-determining region (QRDR) of DNA gyrase (gyrA/gyrB) and/or topoisomerase IV (parC/parE) genes (Eaves et al., 2004) ; active efflux of antibiotic out of the bacterial cell (Baucheron et al., 2002) ; and plasmidmediated quinolone resistance encoded by qnr genes A, B and S (Robicsek et al., 2006a) . The qnr genes encode pentapeptide repeat proteins that block the action of quinolones on bacterial DNA gyrase and topoisomerase IV, resulting in low-level quinolone resistance (Tran et al., 2005a, b) . The first qnr gene was isolated in 1998 from a Klebsiella pneumoniae isolate from Birmingham, Alabama, USA, and was named qnr (later renamed qnrA) (Martinez-Martinez et al., 1998) . qnr genes have been identified in various bacterial species worldwide (Robicsek et al., 2006a) . More recently, a novel quinoloneresistance mechanism has been identified in K. pneumoniae which involves the modification of certain fluoroquinolones by a specific type of aminoglycoside acetyltransferase (Robicsek et al., 2006b) . We report what we believe to be the first discovery of plasmid-mediated quinolone resistance in Salmonella from South Africa, which was identified in a clinical isolate of Salmonella enterica serovar Typhimurium.
A subset (n548) of invasive S. Typhimurium isolates collected by the Enteric Diseases Reference Unit of the National Institute for Communicable Diseases in the year 2006, with MICs for nalidixic acid of ¢32 mg ml 21 , were investigated. Susceptibility testing to antimicrobial agents was determined by the Etest (AB BIODISK). The presence of extended-spectrum b-lactamase (ESBL) activity was investigated using disc diffusion screening methods, as described by the Clinical and Laboratory Standards Institute (CLSI, 2005) . Isolates were screened for qnrA, qnrB and qnrS genes. Individual PCRs were used to screen for each type of qnr gene, using previously described methods (Jacoby et al., 2003 Hopkins et al., 2007) . PCR-positive qnr genes were sequenced. Isolates which were PCR-positive for a qnr gene were further investigated by PCR and sequencing of the QRDR of gyrA, gyrB, parC and parE, using previously described methods (Eaves et al., 2004) . DNA sequencing reactions were carried out using the BigDye Terminator Cycle Sequencing kit (Applied Biosystems) and DNA sequences were determined using the Applied Biosystems 3130 genetic analyser. Analysis of DNA sequences was performed using the DNASTAR Lasergene (version 8.0) software. For nalidixic acid and ciprofloxacin, agar dilution MIC testing was performed in the presence and absence of the efflux pump inhibitor Phe-Arg-b-naphthylamide (Baucheron et al., 2002 
